Trials / Completed
CompletedNCT05051904
A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin
Comparative Safety and Effectiveness of Warfarin, Dabigatran, and Rivaroxaban Among Japanese Patients With Non-valvular Atrial Fibrillation (NVAF) and Concomitant Coronary Artery Disease (CAD)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 39,357 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to evaluate the safety and effectiveness comparisons between warfarin, dabigatran, and rivaroxaban in routine clinical practice among Japanese non-valvular atrial fibrillation (NVAF) patients with concomitant coronary artery disease (CAD).
Conditions
Timeline
- Start date
- 2022-05-17
- Primary completion
- 2022-07-29
- Completion
- 2022-07-29
- First posted
- 2021-09-21
- Last updated
- 2024-03-07
- Results posted
- 2024-03-07
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05051904. Inclusion in this directory is not an endorsement.